<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Low levels of fetuin-A, a systemic calcification inhibitor, are linked to mortality in patients on dialysis </plain></SENT>
<SENT sid="1" pm="."><plain>In contrast, elevated fetuin-A is associated with cardiovascular events in non-renal patients </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated fetuin-A in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo> (PAD) </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: We studied fetuin-A in 76 patients with PAD and <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism (NGM-PAD) and in 129 patients with PAD and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-PAD) </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, 40 patients with <z:mp ids='MP_0002055'>diabetes</z:mp> without any complications (type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-non-PAD) were examined </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-PAD subjects (399 ± 155 μg/ml) had significantly higher fetuin-A levels than type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-non-PAD subjects (247 ± 42; P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>In NGM-PAD subjects (376 ± 144), fetuin-A was significantly higher than in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-non-PAD subjects (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-PAD patients with mediasclerosis had lower fetuin-A than subjects without (P &lt; 0.03) </plain></SENT>
<SENT sid="8" pm="."><plain>Regression analysis in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-PAD subjects revealed that glycated A1C (P &lt; 0.001) and mediasclerosis (P = 0.004) were the strongest predictors of fetuin-A </plain></SENT>
<SENT sid="9" pm="."><plain>Multivariate regression revealed that a 1-SD increase in fetuin-A was associated with an odds ratio (OR) of 2.1 (95% CI 1.1-3.3; P &lt; 0.001) for the prevalence of PAD and an OR of 1.4 (1.0-1.7, P = 0.039) for the prevalence of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In contrast to previous findings, fetuin-A was higher in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-PAD patients than in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-non-PAD patients </plain></SENT>
<SENT sid="11" pm="."><plain>In NGM-PAD patients, fetuin-A was also higher than in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-non-PAD patients </plain></SENT>
<SENT sid="12" pm="."><plain>In type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-PAD patients, fetuin-A was inversely associated with mediasclerosis-the calcification process pathognomonic for diabetic PAD </plain></SENT>
<SENT sid="13" pm="."><plain>This association persisted in multivariate regression, which is in line with the calcification inhibition in coronary heart or <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">renal disease</z:e> </plain></SENT>
</text></document>